Targeting One Type of Immune Cell With Another Slows Cancer Growth in Preclinical Studies

New York, NY (PRWEB) October 25, 2022 -- A new approach to cancer immunotherapy that uses one type of immune cell to kill another—rather than directly

Related Keywords

New York ,United States ,East Harlem ,Brooklyn ,Nassau ,New Providence ,Bahamas ,The ,Spain ,American ,Alfonso Mart ,Luisanna Pia ,Alessia Baccarini ,Miriam Merad ,Gurkan Mollaoglu ,Jalala Khan ,Jaime Mateus ,Brian Brown ,C Matthias Wilk ,Sebastianr Nielsen ,Ashwitha Lakshmi ,Cancer Immunology Research ,Health System ,Jennifer Lipschultz Precision Immunology Institute Pr ,National Institutes Of Health ,Merck Co ,Icahn Genomics Institute ,Applebaum Foundation ,Astrazeneca ,Icahn School Of Medicine At Mount Sinai ,Alliance For Cancer Gene Therapy ,Mount Sinai Health System ,Association Of American Medical Colleges ,Novo Nordisk ,Icahn School ,Mount Sinai ,Associate Director ,Icahn Mount ,Jaime Mateus Tique ,Adam Marks ,Cancer Gene ,National Institutes ,American Medical Colleges ,Icahn Mount Sinai ,Mount Sinai Innovation Partners ,New York City ,Upper East Side ,Sinai Health System ,Mount Sinai Hospital ,Mount Sinai Beth Israel ,Mount Sinai Brooklyn ,Mount Sinai Morningside ,Mount Sinai Queens ,Mount Sinai South Nassau ,Mount Sinai West ,New York Eye ,Ear Infirmary ,Press Release ,